GENFIT S.A. (GNFT)

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Register to leave comments

  • News bot June 8, 2026, 4:11 p.m.

    📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical